1. Generics Bulletin
  2. >>Products

Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

As White House And FDA Ramp Up Coronavirus Research

 
• By Dean Rudge

To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

Donald_Trump
The White House has directed the FDA to expedite testing and possible broader use of hydroxychloroquine and chloroquine • Source: Shutterstock

Teva, Mylan and Novartis’ Sandoz have announced significant steps to meet the “urgent demand” for off-patent hydroxychloroquine sulfate as a potential treatment option for the global COVID-19 pandemic, as the White House directed the US Food and Drug Administration to expedite testing and possible broader use of the drug alongside another anti-malarial drug, chloroquine phosphate.

Sandoz says it is committed to donating up to 130 million doses of its generic US- and EU-approved hydroxychloroquine by the end of May this year, considering current inventory of around 50 million doses; while parent Novartis is supporting ongoing clinical trial

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

More from Products